We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -37.00 | -2.05% | 1,770.00 | 1,769.00 | 1,771.00 | 1,797.00 | 1,760.00 | 1,793.00 | 166,496 | 15:14:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.29 | 3.9B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 3004Q
Hikma Pharmaceuticals Plc
28 November 2016
Notification and public disclosure of transactions by persons discharging managerial responsibilities
The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the pledge by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-Executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.
Said Darwazah
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Said Darwazah
--- --------------------- ----------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Chairman and Chief Executive Officer
/ PDMR
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ----------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 12,250,000 to 20,450,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of Citibank N.A., London Branch.
The Chairman and Chief Executive
is a director of and shareholder
in Darhold Limited with an equity
interest of 21.49%.
--- --------------------- ----------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 8,200,000
--- --------------------- ----------------------------------------
d) Aggregated Aggregated volume: 8,200,000
information Price: GBP0.00p
--- --------------------- ----------------------------------------
e) Date of the 28 November 2016
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ----------------------------------------
Mazen Darwazah
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Mazen Darwazah
--- --------------------- ----------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Executive Vice Chairman / PDMR
--- --------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ---------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ----------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ---------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ----------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 12,250,000 to 20,450,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of Citibank N.A., London Branch.
The Executive Vice Chairman is a
director of and shareholder in Darhold
Limited with an equity interest of
10.82%.
--- --------------------- ----------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 8,200,000
--- --------------------- ----------------------------------------
d) Aggregated Aggregated volume: 8,200,000
information Price: GBP0.00p
--- --------------------- ----------------------------------------
e) Date of the 28 November 2016
transaction
--- --------------------- ----------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ----------------------------------------
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------------
a) Name Mohammed 'Ali' Al-Husry
--- --------------------- ------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Non-Executive Director/ PDMR
--- --------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ------------------------------------------
b) Nature of Extension of a pledge by Darhold
the transaction Limited from 12,250,000 to 20,450,000
Ordinary Shares of 10 pence each
in Hikma Pharmaceuticals PLC in favour
of Citibank N.A., London Branch.
The Non-Executive Director is a director
of and shareholder in Darhold Limited
with an equity interest of 7.95%.
--- --------------------- ------------------------------------------
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 8,200,000
--- --------------------- ------------------------------------------
d) Aggregated Aggregated volume: 8,200,000
information Price: GBP0.00p
--- --------------------- ------------------------------------------
e) Date of the 28 November 2016
transaction
--- --------------------- ------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ------------------------------------------
Peter Speirs, Company Secretary, Responsible for releasing this announcement
28 November 2016
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGCBDBBUDBGLI
(END) Dow Jones Newswires
November 28, 2016 04:59 ET (09:59 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
